利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.047 秒)

    Biomarker to measure drug efficacy in enteropathic disease
    8.
    发明授权
    Biomarker to measure drug efficacy in enteropathic disease 有权
    衡量药物治疗肠病的生物标志物

    公开(公告)号：US08535946B2

    公开(公告)日：2013-09-17

    申请号：US12677501

    申请日：2008-08-28

    申请人： Chaitan Khosla ,  Michael Bethune

    发明人： Chaitan Khosla ,  Michael Bethune

    IPC分类号： G01N33/50 ,  G01N33/48

    CPC分类号： A61K49/0004 ,  G01N33/6848 ,  G01N2333/90245 ,  G01N2800/06 ,  G01N2800/52 ,  Y10T436/142222 ,  Y10T436/145555 ,  Y10T436/147777

    摘要： The response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.

    摘要翻译： 通过检测患者代谢口服CYP3A底物的能力来评估患有肠病的患者对治疗的反应，特别是临床试验环境中的候选治疗。 可以以各种方式监测CYP3A代谢。 方便地，在口服给药后的一段时间内，在患者样品中检测到CYP3A底物的代谢物的出现，例如， 在尿液，血浆，呼吸，唾液等中。CYP3A底物任选地标记，例如。 与同位素，荧光等标签。

    Biomarker to Measure Drug Efficacy in Enteropathic Disease
    9.
    发明申请
    Biomarker to Measure Drug Efficacy in Enteropathic Disease 有权
    生物标志物测定肠病中的药效

    公开(公告)号：US20110027897A1

    公开(公告)日：2011-02-03

    申请号：US12677501

    申请日：2008-08-28

    申请人： Chaitan Khosla ,  Michael Bethune

    发明人： Chaitan Khosla ,  Michael Bethune

    IPC分类号： G01N33/50

    CPC分类号： A61K49/0004 ,  G01N33/6848 ,  G01N2333/90245 ,  G01N2800/06 ,  G01N2800/52 ,  Y10T436/142222 ,  Y10T436/145555 ,  Y10T436/147777

    摘要： The response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.

    摘要翻译： 通过检测患者代谢口服CYP3A底物的能力来评估患有肠病的患者对治疗的反应，特别是临床试验环境中的候选治疗。 可以以各种方式监测CYP3A代谢。 方便地，在口服给药后的一段时间内，在患者样品中检测到CYP3A底物的代谢物的出现，例如， 在尿液，血浆，呼吸，唾液等中。CYP3A底物任选地标记，例如。 与同位素，荧光等标签。